Big Pharma has aimed some choice words at European countries in recent weeks, including calling the UK “uninvestable” and ...

AstraZeneca saw 18% revenue growth in 2024, boosted by key drugs and global innovation. See here to know why we recommend a ...

The AstraZeneca PLC ADR AZN slid 7.39% to $68.46 Friday, on what proved to be an all-around poor trading session for the ...

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

The European Commission has approved a new regimen from AstraZeneca, which combines the company’s durvalumab with ...

Enhertu gains EU approval for treating advanced breast cancer with low HER2 levels, marking a milestone for Daiichi Sankyo & ...

Several pharma CEOs met with Chinese President Xi Jinping in Beijing. President Donald Trump's reciprocal tariffs have mostly ...

AstraZeneca's (LON:AZN) stock up by 7.5% over the past three months. Since the market usually pay for a company’s long-term ...

In early corporate news, BP Chair Helge Lund announced his intention to resign, and AstraZeneca received EU approval for two different therapies. Here is what you need to know at the London market ...

Let’s be realistic, ChatGPT can’t predict the future. But it did do a good job of compiling data from brokerages and banking ...

VANCOUVER, BC / ACCESS Newswire / April 3, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned ...

In a statement, Nxera CEO Chris Cargill said Kaneko’s appointment will help the company “maximize our commercial activities ...